Sivik Global Healthcare LLC Sells 770 Shares of Eli Lilly and Company $LLY

Sivik Global Healthcare LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 15.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,230 shares of the company’s stock after selling 770 shares during the quarter. Eli Lilly and Company comprises 3.0% of Sivik Global Healthcare LLC’s holdings, making the stock its 15th largest holding. Sivik Global Healthcare LLC’s holdings in Eli Lilly and Company were worth $4,894,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Coastal Bridge Advisors LLC acquired a new position in Eli Lilly and Company during the second quarter worth $2,959,000. Mosaic Family Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 70.6% in the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock valued at $4,144,000 after buying an additional 1,430 shares in the last quarter. Moran Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 85.6% in the second quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock valued at $25,072,000 after buying an additional 9,638 shares in the last quarter. Generali Investments Management Co LLC raised its holdings in shares of Eli Lilly and Company by 17.5% in the 2nd quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock valued at $12,258,000 after buying an additional 1,521 shares during the period. Finally, Amundi raised its holdings in shares of Eli Lilly and Company by 9.9% in the 1st quarter. Amundi now owns 5,055,025 shares of the company’s stock valued at $4,649,464,000 after buying an additional 454,549 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 1.2%

Eli Lilly and Company stock traded down $13.92 during midday trading on Tuesday, reaching $1,168.70. The company’s stock had a trading volume of 658,782 shares, compared to its average volume of 2,945,984. Eli Lilly and Company has a fifty-two week low of $783.85 and a fifty-two week high of $1,292.65. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company has a market cap of $1.10 trillion, a P/E ratio of 39.25, a P/E/G ratio of 1.47 and a beta of 0.46. The business has a 50-day simple moving average of $1,175.57 and a 200-day simple moving average of $1,100.31.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. Eli Lilly and Company’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same period in the previous year, the business earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts expect that Eli Lilly and Company will post 36.19 earnings per share for the current fiscal year.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts remain optimistic about Lilly’s earnings and growth prospects. Erste Group raised its FY2026 EPS estimate to $36.55 from $36.45 and its FY2027 forecast to $47.30, while RBC reiterated an “outperform” rating with a $1,500 price target. RBC reiterates outperform rating
• Positive Sentiment: Strong demand for Zepbound and other cardiometabolic medicines is supporting expectations that Lilly could raise its full-year revenue outlook. Analysts and investors also see substantial long-term potential in retatrutide, which could become a larger growth driver than Zepbound if clinical results and commercialization proceed successfully. Lilly revenue outlook
• Positive Sentiment: Phase 3b data for a Taltz-Zepbound combination showed improved skin clearance and weight loss in patients with plaque psoriasis and obesity, potentially expanding Lilly’s ability to target overlapping inflammatory and metabolic conditions. Taltz and Zepbound Phase 3b data
• Positive Sentiment: Lilly is collaborating with Prelude Therapeutics to evaluate a cancer drug combination involving PRT13722, Verzenio and Inluriyo, adding another potential pipeline opportunity. Prelude collaboration with Lilly
• Neutral Sentiment: Lilly’s revenue growth substantially exceeds that of major pharmaceutical peers, but its premium earnings multiple leaves less room for execution mistakes. Investor confidence therefore depends heavily on the company’s pipeline and future obesity-drug launches. Lilly valuation and growth outlook
• Negative Sentiment: A combination treatment produced more weight loss than Zepbound alone but also had materially higher discontinuation rates, raising questions about tolerability, adherence and the commercial potential of future obesity therapies. Lilly weight-loss combination study
• Negative Sentiment: Retatrutide is already facing illicit online sales before approval, highlighting potential regulatory, safety and brand risks for Lilly’s highly anticipated obesity pipeline. Retatrutide black-market sales

Wall Street Analyst Weigh In

A number of equities analysts recently commented on LLY shares. HSBC raised their target price on Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a report on Thursday, September 10th. Bank of America increased their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $1,500.00 price objective on shares of Eli Lilly and Company in a research note on Monday. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an “overweight” rating in a research report on Monday, September 28th. Finally, Berenberg Bank set a $1,400.00 target price on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research note on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,313.43.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald Zakrowski sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 13,500 shares of company stock valued at $15,958,170. Corporate insiders own 0.14% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.